- TheStreet.com•1 hour ago
These 10 dividend aristocrat stocks offer an average high yield of 3% and have increased dividends for 46 consecutive years on average.
- American City Business Journals•2 hours ago
Tokai Pharmaceuticals announced this morning that it’s stopping a late-stage trial of its potential prostate cancer therapy because it has determined it probably won’t show the drug works. Boston-based Tokai (TKAI) said its drug, called galeterone, “will likely not succeed in meeting its primary endpoint of demonstrating an improvement in radiographic progression-free survival” in certain patients who have a shortened version of a so-called androgen receptor — about a fifth of the patient population with prostate cancer. It was data from a mid-stage trial of the drug showing it worked in patient with the so-called “AR-V7 splice variant” that helped Tokai raise $98 million in its September 2014 IPO.
|Bid||124.80 x 900|
|Ask||124.81 x 700|
|52wk Range||81.79 - 126.07|
|Day's Range||124.80 - 125.55|
|Avg Vol (3m)||7,062,514|
As of 1:39 PM EDT. NYSE Real Time Price. Market open.